Cara Therapeutics Inc Stock

$4.80

2.24% today

Nasdaq, Feb 05, 03:46 pm CET

ISIN

US1407551092

Symbol

CARA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cara Therapeutics Inc Stock price

$4.91

-195.25 97.55% 5Y

Nasdaq, Closing price Tue, Feb 04 2025

+0.13 2.72%

ISIN

US1407551092

Symbol

CARA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$22.45m
Enterprise Value	$22.91m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	2.64
P/S ratio (TTM) P/S ratio	2.58
P/B ratio (TTM) P/B ratio	31.74
Revenue growth (TTM) Revenue growth	-59.08%
Revenue (TTM) Revenue	$8.69m
EBIT (operating result TTM) EBIT	$-82.39m
Free Cash Flow (TTM) Free Cash Flow	$-77.34m
Cash position	$43.54m
EPS (TTM) EPS	$-20.99
P/E forward	negative
P/S forward	2.37
EV/Sales forward	1.05
Short interest	2.00%

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Get Started for Free Today

Cara Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Cara Therapeutics Inc forecast:

1x Buy

20%

4x Hold

80%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Cara Therapeutics Inc forecast:

Buy

20%

Hold

80%

Analyst Estimates with Stock Price Targets

Financial data from Cara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	8.69 8.69	59% 59% 100%
- Direct Costs	1.50 1.50	81% 81% 17%
Gross Profit	7.18 7.18	46% 46% 83%
- Selling and Administrative Expenses	28 28	10% 10% 326%
- Research and Development Expense	61 61	42% 42% 701%
EBITDA	-82 -82	31% 31% -945%
- Depreciation and Amortization	0.27 0.27	85% 85% 3%
EBIT (Operating Income) EBIT	-82 -82	31% 31% -948%
Net Profit	-96 -96	18% 18% -1,099%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cara Therapeutics Inc Stock News

Neutral

Business Wire

●

30 days ago

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the comb...

Neutral

GlobeNewsWire

●

about one month ago

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.

Neutral

Business Wire

●

about 2 months ago

Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, pre-Merger Car...

More Cara Therapeutics Inc News

Company Profile

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Head office	United States
CEO	Christopher Posner
Employees	55
Founded	2004
Website	www.caratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now